IP Library Granted Patent US 7,097,984
Granted Patent B2
US 7,097,984 · App. 10/209,779 · Granted Aug 29, 2006

Method of utilizing neurotrophins to manipulate reproductive capacity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,097,984
App. No.
10/209,779
Granted
Aug 29, 2006
Kind
B2
Abstract

Methods and kits are provided for manipulating and predicting the reproductive capacity of a female subject. The presence of endogenous neurotrophins and addition of exogenous neurotrophins, particularly BDNF, NT-4/5, and NGF, increase the reproductive capacity of a female patient by binding to receptors on the oocytes and stimulating maturation of the oocytes. Administration of antagonists act as a contraceptive because the antagonists prevent the neurotrophins from binding to oocyte receptors. Neurotrophins may also be used to stimulate the maturation of oocyte in vitro.

Claims (10)

1. A method for testing viability of an oocyte from a woman, comprising:

extracting at least one oocyte;

administering brain derived neurotrophic factor, NT-4/5, or NGF to the oocyte under condition at which the brain derived neurotrophic factor, NT-4/5, or NGF binds to a brain derived neurotrophic factor, NT-4/5, or NGF receptors on the oocyte;

washing the oocyte to remove any excess, unbound brain derived neurotrophic factor, NT-4/5, or NGF;

administering monoclonal antibodies with a related specific binding affinity for brain derived neurotrophic factor, NT-4/5, or NGF under conditions at which the monoclonal antibodies bind to the bound brain derived neurotrophic factor, NT-4/5, or NGF on the oocyte;

washing the oocytes to remove any unbound monoclonal antibodies; and

measuring bound monoclonal antibodies,

wherein the presence of bound monoclonal antibodies indicative of brain derived neurotrophic factor, NT-4/5, or NGF bound to the oocyte is a positive prognosticator of oocyte viability and the absence of bound monoclonal antibody indicative of brain derived neurotrophic factor, NT-4/5, or NGF bound to the oocyte is a negative prognosticator of oocyte viability.

2. The method of claim 1 , wherein the antibodies are labeled.

3. The method of claim 2 , wherein the labeling material is fluorescent material or radioactive material.

Assignments (2)
CONFIRMATORY LICENSE Recorded Mar 8, 2022
From: RUTGERS, THE STATE UNIV. OF N.J.
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 059197/0857 →
NUNC PRO TUNC ASSIGNMENT Recorded Aug 13, 2014
From: THE UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
To: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Reel/Frame 033525/0369 →